Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.

This year, Summit Therapeutics Inc. (SMMT) leads the parade of winners among large stocks (those with a market value of $10 ...

Archived copies of the webcasts will be available for up to one year by visiting the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.

On Monday, Summit Therapeutics Inc (SMMT) stock saw a modest uptick, ending the day at $21.77 which represents a slight increase of $0.36 or 1.68% from the prior close of $21.41. The stock opened at ...

While it remains to be seen how Summit's oncology turn ultimately shakes out, at this point it is indeed looking like a ...

JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT), noting the company’s initial focus on infectious ...

Fintel reports that on November 4, 2024, JMP Securities initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a ...

Now this is a fine way to begin a week on the stock market. Summit Therapeutics (NASDAQ: SMMT) saw its stock price rise notably Monday, on the happy news that an analyst has initiated coverage ...

On Thursday, Summit Therapeutics Inc (SMMT) stock saw a decline, ending the day at $18.59 which represents a decrease of $-0.06 or -0.32% from the prior close of $18.65. The stock opened at $18.75 and ...

On Monday, Summit Therapeutics plc (NASDAQ:SMMT) received a Market Outperform rating from JMP Securities, accompanied by a $32.00 price target. The new coverage reflects a positive outlook on the ...

Presentation to highlight advances in fibrostenotic Crohn’s Disease and the potential of localized PDE4 inhibitionCarlsbad, CA, Nov. 14, 2024 ...